QUILLIVANT XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QUILLIVANT XR (QUILLIVANT XR).
Extended-release oral suspension formulation of methylphenidate, a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their synaptic concentrations. The exact therapeutic effect in ADHD is unknown but is thought to involve dopaminergic and noradrenergic pathways in the prefrontal cortex.
| Metabolism | Primarily metabolized by de-esterification via carboxylesterase 1 (CES1) to ritalinic acid, a major inactive metabolite. Minor pathways include hydroxylation via CYP2D6 to p-hydroxy-methylphenidate, which is further glucuronidated. Methylphenidate is not significantly metabolized by CYP450 enzymes. |
| Excretion | Primarily renal (approximately 60% as unchanged drug); fecal excretion accounts for <5%. |
| Half-life | Approximately 4 hours; extended-release formulation provides therapeutic levels for ~12 hours. |
| Protein binding | <10% bound to plasma proteins. |
| Volume of Distribution | 3–4 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Approximately 70% after oral administration. |
| Onset of Action | Oral: ~1-2 hours. |
| Duration of Action | Up to 12 hours due to extended-release delivery. |
| Molecular Weight | 323.4 |
Initial: 25 mg orally once daily in the morning; may increase weekly in 25 mg increments based on tolerability and response. Maximum: 75 mg once daily.
| Dosage form | FOR SUSPENSION, EXTENDED RELEASE |
| Renal impairment | eGFR 30-89 mL/min: No adjustment needed. eGFR <30 mL/min: Not recommended due to lack of data. |
| Liver impairment | Child-Pugh A: No adjustment needed. Child-Pugh B-C: Not recommended due to lack of data. |
| Pediatric use | Children 6-12 years: Initial 25 mg once daily; may increase to 50 mg after 1 week. Adolescents 13-17 years: Initial 25 mg once daily; may increase to 50 mg after 1 week; maximum 75 mg/day. |
| Geriatric use | Start at low end of dosing range (25 mg once daily) due to increased sensitivity and potential for decreased renal function. |
| 1st trimester | Avoid, especially during first trimester. Dextroamphetamine/amphetamine is teratogenic in animal studies; human data limited but suggests increased risk of congenital malformations (oral clefts, cardiac anomalies). |
| 2nd trimester | Use only if benefit clearly outweighs risk. Potential for adverse fetal effects including prematurity and growth restriction. |
| 3rd trimester | Avoid due to risk of neonatal withdrawal, low birth weight, and possible behavioral effects. May cause neonatal tachycardia, jitteriness, and poor feeding. |
Clinical note
Comprehensive clinical and safety monograph for QUILLIVANT XR (QUILLIVANT XR).
| Placental transfer | Crosses placenta; fetal/neonatal plasma concentrations may be 30-50% of maternal levels. |
| Breastfeeding | Excreted into breast milk in small amounts. Potential for infant stimulation, insomnia, and growth suppression. American Academy of Pediatrics recommends caution; use only if essential and monitor infant for adverse effects. Consider alternative agents if possible. |
■ FDA Black Box Warning
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including QUILLIVANT XR, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
| Serious Effects |
Hypersensitivity to amphetamine productsConcurrent use or within 14 days of MAOI therapyGlaucomaHyperthyroidismAgitated statesHistory of drug abuseCardiovascular disease including moderate to severe hypertension, advanced arteriosclerosis, symptomatic cardiac disease, or structural cardiac abnormalities
| Precautions | Serious cardiovascular events: Sudden death, stroke, myocardial infarction; avoid in patients with known structural cardiac abnormalities or serious arrhythmias, Blood pressure and heart rate increases: Monitor regularly, Psychiatric adverse reactions: May exacerbate pre-existing psychosis, mania, or aggression; screen for bipolar disorder prior to treatment, Seizures: Use with caution in patients with a history of seizures, Priapism: Seek immediate medical attention for prolonged erections, Peripheral vasculopathy: Raynaud's phenomenon; monitor for digital changes, Long-term suppression of growth: Monitor height and weight during treatment |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C. In animal studies, methylphenidate, the active component, demonstrated teratogenic effects (increased incidence of fetal malformations) at doses approximately 2-3 times the maximum recommended human dose. In first trimester, increased risk of cardiac malformations reported in some human observational studies. Second and third trimester: risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome (including irritability, feeding difficulties). Data insufficient to quantify absolute risk. |
| Fetal Monitoring | Maternal: Blood pressure and heart rate monitoring at each visit; assess for signs of cardiovascular adverse events. Fetal: Ultrasound to monitor fetal growth and anatomy; consider fetal echocardiography if first trimester exposure. Neonatal: Monitor for withdrawal symptoms (irritability, hypertonia, feeding problems) and growth parameters after delivery. |
| Fertility Effects | In animal studies, methylphenidate did not impair fertility. Human data are limited; however, stimulants may affect reproductive hormones: case reports of irregular menstruation and galactorrhea. No conclusive evidence of reduced fertility. Advise preconception counseling. |
| Food/Dietary |
| Avoid high-fat meals around the time of dosing as they may decrease peak concentration and delay absorption. Grapefruit juice may increase methylphenidate levels; avoid concurrent use. Alcohol may enhance CNS depressant effects and alter drug release; avoid alcohol. |
| Clinical Pearls | QUILLIVANT XR is an extended-release liquid formulation of methylphenidate. Shake bottle vigorously for at least 10 seconds before each dose. Dosing is based on the once-daily total dose of immediate-release methylphenidate. Avoid use in patients with glaucoma, motor tics, or family history of Tourette syndrome. Monitor for blood pressure and heart rate changes, and for potential growth suppression in children. Do not administer with or after high-fat meals as they may reduce peak concentration and delay absorption. Avoid concurrent use with MAOIs or within 14 days of discontinuation. |
| Patient Advice | Take exactly as prescribed once daily in the morning with or without food. · Shake the bottle very well for at least 10 seconds before each dose. · Use the provided oral dosing syringe or dosing cup; clean after each use. · Avoid alcohol while taking this medication. · Report any chest pain, shortness of breath, or fainting to your doctor immediately. · Do not crush, chew, or split the liquid; it is a suspension that must be shaken. · Store at room temperature away from heat, moisture, and light. · Do not share this medication with others; it is a controlled substance. |